CRYO-CELL, a Leader in Cord Blood Banking, Has Announced Its Transfer to the NYSE American Stock Exchange.

CRYO-CELL, a Leader in Cord Blood Banking, Has Announced Its Transfer to the NYSE American Stock Exchange.

CRYO-CELL International, Inc. (NASDAQ: CCEL), which was the world’s first private cord blood bank to separate and store stem cells in 1992, said today that it will switch from the Nasdaq Capital Market to the NYSE American stock exchange on August 30, 2022.

David Portnoy, Chairman and Co-CEO of CRYO-CELL International, Inc. (NASDAQ:CCEL), said, The New York Stock Exchange has been in the stock trading business for more than 225 years and is the world leader in listings for many industries, including pharmaceuticals and technology. After a lot of thought, we decided that the NYSE American stock exchange is a better fit for CRYO-CELL International, Inc. (NASDAQ:CCEL) right now. Hopefully, this will make it easier for our shareholders to trade stocks. Also, CRYO-CELL International, Inc. (NASDAQ: CCEL) will be in line with the rules of the NYSE American right away in terms of how our Board of Directors is currently set up.

The Nasdaq Capital Market is expected to stop trading on August 29, 2022. The “CCEL” symbol will still be used to trade Cryo-common Cell’s stock.

What Cryo-Cell International, Inc. Is and Does

CRYO-CELL International, Inc. (NASDAQ:CCEL) is the first private cord blood bank in the world. It was started in 1989. More than 450,000 parents from 87 countries have given their baby’s cord blood and cord tissue stem cells to CRYO-CELL International, Inc. (NASDAQ:CCEL). Cryo-Cell International has a public banking program with Duke University that is separate from its private bank. CRYO-CELL International, Inc. (NASDAQ:CCEL)‘s bank has given cord blood for more than 600 transplants and runs cord blood donation sites in hospitals all over the U.S., such as Cedars-Sinai Hospital in Los Angeles and Baptist Hospital in Miami. Cryo-facility Cell’s is registered with the FDA, follows cGMP/cGTP standards, and has licenses in all states that require them. In addition to having AABB accreditation as a cord blood facility, CRYO-CELL International, Inc. (NASDAQ: CCEL) was the first U.S. cord blood bank (for private use only) to get FACT accreditation for meeting the highest quality standards for cord blood set by any internationally recognized, independent accrediting organization. CRYO-CELL International, Inc. (NASDAQ:CCEL) is the only company that can use PrepaCyte-CB, the most advanced cord blood processing technology on the market. ‎

Cryo-goal cells is to offer the best services for freezing cord blood and cord tissue, to develop, make, and give out cellular therapies that make a big difference in the lives of patients all over the world, and to offer the highest quality and most cost-effective biostorage solutions. CRYO-CELL International, Inc. (NASDAQ: CCEL) signed a license agreement with Duke University in February 2021. The Company believes that this is the first step toward CRYO-CELL International, Inc. (NASDAQ:CCEL) becoming an independent, vertically integrated cellular therapy company. CRYO-CELL International, Inc. (NASDAQ: CCEL) started ExtraVault in March 2022 so that biopharmaceutical companies and healthcare institutions could use its expertise in biostorage and distribution.

Featured Image: Megapixl @Chatdesbalkans